Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Although daratumumab-containing regimens improve the outcome of relapsed multiple myeloma (MM), the disease remains incurable. We recently published the outcome of daratumumab-based treatment in 583 relapsed myeloma patients in real-world practice (LeBlanc R et al. Br J Haematol 2022). Here we present outcomes of these patients at time of subsequent treatments for relapse immediately after their daratumumab-containing regimen.